SecBot SecBot
PRESS-RELEASE ·Filed Apr 28, 2026

WVE

Wave Life Sciences USA, Inc.
BULLISH
Impact 7/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The significant Q1 beat and positive pipeline updates (WVE-007 Phase 2a, WVE-006 data) are likely to drive the stock higher. Monitor the ATS conference in May for WVE-006 data and any regulatory feedback on accelerated approval.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.52
T+0 close · Apr 28, 2026 · via day close
Latest settled
−23.14%
T+60 · $5.78
Vs SPY
−27.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 28 $7.52entry
  2. T+1 · 7mo ago −6.25%α −6.24% · $7.05
  3. T+5 · 7mo ago −0.66%α −2.36% · $7.47
  4. T+20 · 6mo ago −15.16%α −20.63% · $6.38
  5. T+60 · 4mo ago −23.14%α −27.13% · $5.78
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Wave Life Sciences reported Q1 2026 revenue of $38.2M (vs consensus $7.9M) and EPS of -$0.13 (vs consensus -$0.31), representing a massive beat. Net loss improved to $26.1M from $46.9M a year ago, and the company maintained a strong cash position of $544.6M. Pipeline catalysts include FDA acceptance of WVE-007 Phase 2a and upcoming AATD data.

Key Financial Metrics

EPS
−$0.13
est −$0.31 · +58.1%
Revenue
$38.2M
est $7.9M · +384.0% · +316.0% YoY
Rating
strong beat

Key Facts

  • Q1 2026 revenue $38.2M vs consensus $7.9M (beat by 384%)
  • Q1 2026 EPS -$0.13 vs consensus -$0.31 (beat by 58%)
  • Net loss improved to $26.1M from $46.9M YoY
  • Cash and equivalents $544.6M, runway into Q3 2028
  • FDA accepted Phase 2a multidose portion for WVE-007 (obesity), initiation on track for Q2 2026
  • WVE-006 AATD data at ATS in May 2026; regulatory feedback on accelerated approval expected mid-2026

Financial Impact

Revenue beat of $30.3M vs consensus; EPS beat of $0.18; net loss improved by $20.8M YoY

revenueepsnet losscash

Risk Factors

  • Clinical trial delays or failures for WVE-007 and WVE-006
  • Dilution from increased share count (200M vs 163M YoY)
  • Still in net loss, though improving

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3282474

Track record

16 reports on WVE

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +17.42% at T+5 after the Mar 26, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.13 to $2.87 Now $2.87 −8.31% ▼ −8.31% −6.40% vs SPY
  2. Oct 27, 202620d ago SC 13G Neutral 4/10 Entry $3.64 to $3.63 Now $2.87 −21.15% ▼ −0.27% +0.11% vs SPY
  3. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
  4. Oct 27, 202620d ago 8-K Bullish 6/10 No price data
  5. Oct 27, 202620d ago Press Release Neutral 5/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
  6. Oct 14, 20264w ago DEF 14A Neutral 4/10 Entry $3.19 to $3.13 Now $2.87 −10.03% ▼ −1.88% −0.77% vs SPY
  7. Sep 30, 20266w ago Press Release Bullish 5/10 Entry $3.70 to $3.88 Now $2.87 −22.43% ▲ +4.86% +4.69% vs SPY
  8. Aug 13, 202613w ago Insider Cluster Neutral 3/10 Entry $5.41 to $5.09 Now $2.87 −46.95% ▼ −5.92% −5.44% vs SPY
  9. May 18, 202626w ago Press Release Bullish 7/10 Entry $6.14 to $6.19 Now $2.87 −53.26% ▲ +0.81% −0.23% vs SPY
  10. Apr 28, 202628w ago 8-K Bullish 7/10 No price data
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 28, 2026